Department of Otolaryngology-Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
University of California Irvine School of Medicine, University of California Irvine, Irvine, California, USA.
Otolaryngol Head Neck Surg. 2023 Jun;168(6):1353-1361. doi: 10.1002/ohn.295. Epub 2023 Feb 5.
To determine if antithrombotic therapy improves head and neck microvascular free flap survival following anastomotic revision.
A retrospective review of all patients with microvascular free tissue transfer to the head and neck between August 2013 and July 2021.
Otolaryngology-Head and Neck Surgery Departments at University of Alabama at Birmingham, University of Colorado, and University of California Irvine.
Perioperative use of anticoagulation, antiplatelets, intraoperative heparin bolus, tissue plasminogen activator (tPA) and vasopressor use, and leech therapy were collected plus microvascular free flap outcomes. The primary endpoint was free flap failure. Analyses of free flaps that underwent anastomotic revision with or without thrombectomy were performed.
A total of 843 microvascular free flaps were included. The overall rate of flap failure was 4.0% (n = 34). The overall rate of pedicle anastomosis revision (artery, vein, or both) was 5.0% (n = 42) with a failure rate of 47.6% (n = 20) after revision. Anastomotic revision significantly increased the risk of flap failure (odds ratio [OR] 52.68, 95% confidence interval [CI] [23.90, 121.1], p < .0001) especially when both the artery and vein were revised (OR 9.425, 95% CI [2.117, 52.33], p = .005). Free flap failure after the anastomotic revision was not affected by postoperative antiplatelet therapy, postoperative prophylactic anticoagulation, intraoperative heparin bolus, tPA, and therapeutic anticoagulation regardless of which vessels were revised and if a thrombus was identified.
In cases of microvascular free tissue transfer pedicle anastomotic revision, the use of antithrombotic therapy does not appear to significantly change free flap survival outcomes.
确定抗血栓治疗是否能改善吻合口修复后的头颈部微血管游离皮瓣存活。
对 2013 年 8 月至 2021 年 7 月间在阿拉巴马大学伯明翰分校、科罗拉多大学和加利福尼亚大学欧文分校耳鼻喉科接受微血管游离组织移植到头颈部的所有患者进行回顾性研究。
阿拉巴马大学伯明翰分校、科罗拉多大学和加利福尼亚大学欧文分校耳鼻喉科。
收集围手术期抗凝、抗血小板、术中肝素冲击、组织纤溶酶原激活物(tPA)和血管加压素的使用以及水蛭治疗情况,以及微血管游离皮瓣的结果。主要终点是游离皮瓣失败。对行吻合口修复术的游离皮瓣进行了分析,包括是否行血栓切除术。
共纳入 843 例微血管游离皮瓣。皮瓣失败的总体发生率为 4.0%(n=34)。吻合口修复(动脉、静脉或两者)的总体发生率为 5.0%(n=42),修复后失败率为 47.6%(n=20)。吻合口修复显著增加了皮瓣失败的风险(比值比[OR]52.68,95%置信区间[CI] [23.90,121.1],p<0.0001),尤其是当动脉和静脉均修复时(OR 9.425,95%CI [2.117,52.33],p=0.005)。吻合口修复后的游离皮瓣失败不受术后抗血小板治疗、术后预防性抗凝、术中肝素冲击、tPA 和治疗性抗凝的影响,无论修复了哪些血管以及是否发现血栓。
在微血管游离组织移植蒂吻合口修复的情况下,抗血栓治疗的使用似乎并不能显著改变游离皮瓣的存活结果。